Method
Level · gp.fundamentals.debt_to_revenue
Raw value 0.00% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTYarrow Bioscience, Inc.'s latest supported as-filed period reports revenue of $97,000, 40.6% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 0.00% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -2053.61% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 40.58% · CORE
Level · gp.fundamentals.operating_margin
Raw value -3197.94% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 812.37% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 449.48% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents increased 4.0%; Operating cash flow increased 81.6%.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 40.6%; Operating margin moved 773250 bp higher; Operating income increased 58.9%.
3 evidence-backed componentsOperating cash flow changed +81.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
YARW · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001104659-26-106699SEC ↗8-K/AAug 13, 2026Period Jul 24, 20260001104659-26-095925SEC ↗10-QAug 13, 2026Period Jun 30, 20260001566044-26-000010SEC ↗4Jul 30, 2026Period Jul 29, 20260001104659-26-088665SEC ↗8-KJul 30, 2026Period Jul 29, 20260001104659-26-088662SEC ↗4Jul 29, 2026Period Jul 27, 20260001104659-26-088371SEC ↗4Jul 29, 2026Period Jul 27, 20260001104659-26-088370SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating income changed +58.9% from the comparable as-filed period.
Revenue changed +40.6% from the comparable as-filed period.
Operating margin changed +773250 basis points from the comparable as-filed period.
Net income changed +47.7% from the comparable as-filed period.
Shares outstanding changed -89.5% from the comparable as-filed period. The change ranks at the 50th percentile of 8 prior comparable changes. This reverses 7 consecutive comparable moves in the opposite direction.
Research & development changed -83.9% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001104659-26-087601